Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records

References

• Oppenheimer E, Tobutt C, Taylor C, et al. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994; 89: 1299–1308
   PubMed Web of Science ®Google Scholar
• Hser Y I, Hoffman V, Grella C E, et al. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58: 503–508
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W, Lynskey M, . Illicit drug use. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Chapter 13, M Ezzati, A D Lopez, A Rodgers, R Murray, et al. World Health Organization, Geneva 2004; 1109–1176
   Google Scholar
• Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 1995; 40: 139–150
   PubMed Web of Science ®Google Scholar
• Ward J, Hall W, Mattick R P. Role of maintenance treatment in opioid dependence. Lancet 1999; 353: 221–226
   PubMed Web of Science ®Google Scholar
• Caplehorn J RM, Dalton M SYN, Halder F, et al. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 1996; 31: 177–196
   PubMed Web of Science ®Google Scholar
• Mattick R P, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003, Issue 2
   Google Scholar
• Davids E, Gastpar M. Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 2004; 14: 209–216
   PubMed Web of Science ®Google Scholar
• Fiellin D A, Kleber H, Trumple-Hejduk J G, et al. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004; 27: 153–159
   PubMed Web of Science ®Google Scholar
• Mattick R P, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003, Issue 2
   Google Scholar
• Renault P F. Treatment of heroin-dependent persons with antagonists: current status. National Institute on Drug Abuse, Maryland 1981, Report No. 28: NIDA Research Monograph no. 28
   Google Scholar
• Tucker T K, Ritter A J, Maher C, et al. Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug Alcohol Rev 2004; 23: 299–309
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006, Issue 1
   Google Scholar
• Estimating the prevalence of drug abuse using the mortality multiplier method: an overview, M Frischer, et al. Office for Official Publications of the European Communities, Luxembourg 1998
   Google Scholar
• Frischer M, Hickman M, Kraus L, et al. A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction 2001; 96: 1465–1476
   PubMed Web of Science ®Google Scholar
• Caplehorn J RM, Drummer O H. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999; 170: 104–109
   PubMed Web of Science ®Google Scholar
• Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990 – 1995. Addiction 2000; 95: 77–84
   PubMed Web of Science ®Google Scholar
• Corkery J M, Schifano F, Ghodse A H, et al. The effects of methadone and its role in fatalities. Hum Psychopharmacol 2004; 19: 565–576
   PubMed Web of Science ®Google Scholar
• Milroy C M, Forrest A RW. Methadone deaths: a toxiciological analysis. J Clin Pathol 2000; 53: 277–281
   PubMed Web of Science ®Google Scholar
• Walsh S L, Preston K L, Stitzer M L, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569–580
   PubMed Web of Science ®Google Scholar
• Mattick R P, Digiusto E, Doran C M, et al. National evaluation of pharmacotherapies for opioid dependence: report of results and recommendations. National Drug and Alcohol Research Centre, Sydney 2004
   Google Scholar
• Lintzeris N, Clark N, Muhleisen P, et al. National clinical guidelines and procedures for the use of buprenorphine in the treatment of heroin dependence. Department of Health and Aged Care, Canberra 2001
   Google Scholar
• Schifano F, Corkery J, Gilvarry E, et al. Buprenorphine mortality, seizures and prescription data in the UK, 1980 – 2002. Hum Psychopharmacol 2005; 20: 343–348
   Google Scholar
• Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict 2004; 13(Suppl 1)S17–S28
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs. buprenorphine in France. JAMA 2001; 285: 3
   Google Scholar
• Reisine T, Pasternak G. Opioid analgesics and antagonists. Goodman & Gilman's The pharmacological basis of therapeutics9th edn, J G Hardman, L E Limbird. McGraw-Hill, Sydney 1996
   Google Scholar
• Bell J, Kimber J, Lintzeris N, et al. Clinical guidelines and procedures for the use of naltrexone in the management of opioid dependence. Australian Government Department of Health and Ageing, Canberra 2003
   Google Scholar
• Hamilton R, Olmedo R, Shah S, et al. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med 2002; 9: 63–68
   PubMed Web of Science ®Google Scholar
• Digiusto E, Shakeshaft A, Ritter A, et al. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004; 99: 450–460
   PubMed Web of Science ®Google Scholar
• Ritter A J. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Aust NZ J Psychiatry 2002; 36: 224–228
   PubMed Web of Science ®Google Scholar
• Barker B, Conroy E, Degenhardt L, et al. Global indicators for monitoring the illicit drug environment of NSW. National Drug and Alcohol Research Centre, University of New South Wales, Sydney 2004
   Google Scholar
• Gibson A, Degenhardt L. Mortality related to naltrexone in the treatment of opioid dependence: a comparative analysis. National Drug and Alcohol Research Centre, Sydney 2005
   Google Scholar
• Bird S M, Hutchinson S J. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996 – 99. Addiction 2003; 98: 185–190
   PubMed Web of Science ®Google Scholar
• Miotto K, McCann M J, Rawson R A, et al. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 1997; 45: 131–134
   PubMed Web of Science ®Google Scholar
• Foy A, Sadler C, Taylor A. An open trial of naltrexone for opiate dependence. Drug Alcohol Rev 1998; 17: 167–174
   PubMed Web of Science ®Google Scholar
• Bell J R, Young M R, Masterman S C, et al. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999; 171: 26–30
   PubMed Web of Science ®Google Scholar
• Hall W, Wodak A. Is naltrexone a cure for heroin dependence? The evidence so far is not promising. Med J Aust 1999; 171: 9–10
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson D R. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. J Clin Psychiatry 1984; 45: 46–48
   PubMed Web of Science ®Google Scholar
• Hulse G K, O'Neil G, Hatton M, et al. Use of oral and implantable naltrexone in the management of the opioid impaired physician. Anaesth Intens Care 2003; 31: 196–201
   PubMed Web of Science ®Google Scholar
• Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1- month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003; 8: 211–217
   PubMed Web of Science ®Google Scholar
• Brewer C. Naltrexone implants for opiate addiction: new life for a middle-aged drug. Pharm J 2001; 267: 260
   Google Scholar
• Comer S D, Collins E D, Kleber H D, et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 2002; 159: 351–360
   PubMed Web of Science ®Google Scholar
• Carreno J E, Alvarez C E, San Narciso G I, et al. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict Biol 2003; 8: 429–438
   PubMed Web of Science ®Google Scholar
• Hulse G K, Tait R J. A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in ‘high-risk’ adolescent heroin users. Addict Biol 2003; 8: 337–342
   PubMed Web of Science ®Google Scholar
• Oliver P. Fatal opiate overdose following regimen changes in naltrexone treatment. Addiction 2005; 100: 560–563
   PubMed Web of Science ®Google Scholar
• Arnold-Reed D E, Hulse G K, Hansson R C, et al. Blood morphine levels in naltrexone-exposed compared to non-naltrexone-exposed fatal heroin overdoses. Addict Biol 2003; 8: 343–350
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D. Dual dependence: assessment of dependence upon alcohol and illicit drugs, and the relationship of alcohol dependence among drug misusers to patterns of drinking, illicit drug use and health problems. Addiction 2002; 97: 169–178
   PubMed Web of Science ®Google Scholar
• Buster M C, van Brussel G H, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 2002; 97: 993–1001
   PubMed Web of Science ®Google Scholar